Introduction
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Burkholderia pseudomallei is a Gram-negative, facultative intracellular pathogen that causes 52 melioidosis, a serious and often fatal disease in humans and animals (1). While the incidence 53 of melioidosis is particularly high in Southeast Asia and northern Australia, recent reports 54 have expanded the endemic region to include India and Brazil. Sporadic cases of melioidosis 55 have also been reported in various parts of the Caribbean, Central and South America, the 56 Middle East and Africa (2, 3). B. pseudomallei can be isolated from environmental niches 57 such as rice paddies, still or stagnant waters and moist soils which predominate in the tropics 58 (4), and it is believed that these habitats are the primary reservoirs from which susceptible 59 hosts acquire infections. Routes of infection include inhalation, ingestion and percutaneous 60 inoculation (5). 61 Melioidosis has a broad clinical spectrum and may manifest as acute localized 62 infections, acute pulmonary infections and fulminating septicemias or as chronic disease (6, 63 7). Remarkably, 20% of all community-acquired septicemias in northeast Thailand and 32% 64 of community-acquired bacteremic pneumonias in northern Australia are due to B.
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pseudomallei infections (8, 9) . Because of the non-specific presentation, the lack of rapid 66 diagnostic tests and the intrinsic resistance of B. pseudomallei to commonly used antibiotics, 67 diagnosis and treatment of melioidosis can be challenging. In the absence of optimal 68 chemotherapeutic intervention, mortality rates associated with acute human melioidosis 69 remain unacceptably high (40 -50% in northeast Thailand and 19% in Australia (9, 10) ). At 70 present, there are no human vaccines available for immunization against this emerging 71 infectious disease (for recent reviews see (11) (12) (13) Bsa type III secretion system, the VirAG two-component regulatory system and the cluster 1 77 type VI secretion system (for recent reviews see (5, 14) ΔpurM derivative of 1026b) were created to enable us to produce these polysaccharides in a 221 safer and more cost-effective manner without the requirement for BSL-3 containment (19, 222 35).
To facilitate the construction of the glycoconjugates described in this study, the OPS 224 and CPS antigens purified from RR2808 and RR2683 were chemically activated with sodium 225 periodate and covalently linked to cBSA via reductive amination to produce OPS2B1 and 226 CPS2B1 ( Figure 1A ). Following conjugation, the samples were examined by SDS-PAGE.
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Results of these analyses demonstrated that in both instances the polysaccharides had compared to controls. The control mice in this study had a median time to death of 12.5 days.
270
It was not possible however, to calculate a median time to death for the CPS2B1-immunized 271 mice since by day 21 only 10% had succumbed to infection. The survival curves of the CPS2B1 and adjuvant mice were significantly different (p=0.0059; Figure 4B each group. Significance at the 95% confidence limit for organ bacterial counts was
